Technology Listings


Combination Therapy Using Small Molecule Conjugation to Reovirus for TNBC Treatment

Application

Small molecule inhibitor doxorubicin hydrochloride (Dox) conjugated to reovirus for targeted combination therapy of triple-negative breast cancer (TNBC).

Key Benefits
  • Targeted treatment that directly infects and kills breast cancer cells.
  • Increased cytopathicity, cytotoxicity and faster induction of cell death than virus alone.
  • Enhanced selective delivery of doxorubicin to TNBC cells.
Market Summary

Triple-negative breast cancer (TNBC) is when the breast cancer cells lack the three most common receptors known to fuel breast cancer growth—estrogen, progesterone, and hormone epidermal growth factor receptor 2 (HER-2). TNBC constitutes approximately 15% of all breast cancer, has a higher rate of relapse, and shorter overall survival after metastasis than other subtypes of breast cancer. Since the tumor cells lack the receptors targeted by common treatments like hormone therapy, receptor-specific drugs are ineffective. Current therapies for TNBC are surgical removal of tumor, non-specific cytotoxic chemotherapy, and radiation. Chemotherapy and radiation can cause significant side-effects including damage to healthy cells and tissue.

Technical Summary

Emory University and Children’s Healthcare of Atlanta researchers have engineered multiple constructs of reovirus with enhanced attachment, infectivity, and ability to induce cell death in Triple-Negative Breast Cancer (TNBC) cells. The researchers have also developed a combination therapy for TNBC treatment by conjugation of small molecule inhibitor doxorubicin hydrochloride (Dox) to reovirus (Reo-dox). In several TNBC cells, Reo-dox robustly enhanced TNBC cell killing without affecting the ability of the virus to infect and replicate. Reo-dox induces DNA double-strand break damage at similar levels as doxorubicin alone. Together, these findings show that this conjugation provides a potent therapeutic method to directly target and kill cancer cells while minimizing toxicity to healthy cells and tissues in a multi-faceted combinatorial approach.

Developmental Stage

Doxorubicin-conjugated reovirus has been synthesized and successfully tested yielding clinically significant results.

Publication:

Berry, J. T. et al. (2019). AACR Annual Meeting 2019; Cancer Res 2019; 79(13 Suppl): Abstract no. 2169.

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
PCT PCT PCT/US2019/036151   6/7/2019   12/7/2020 Pending
Tech ID: 16161
Published: 10/11/2019
Category
Therapeutics

Contact
Sarah Wilkening
Licensing Associate
Emory University
(404) 727-1969
sarah.wilkening@emory.edu

Inventor(s)
Bernardo Mainou
Roxana Rodriguez
Angela Berger

Keywords
Biologic
Oncology
Small Molecule
Women's Health